Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday.

The high cost of Zolgensma, a one-time gene therapy used to treat spinal muscular atrophy (SMA) in children under two, is to limited patien...

Asserting that it's a really exciting moment to be in the world of medicine and R&D, Narasimhan said: "RNA therapeutics are opening up a wh...

The company started a strategic review of Sandoz last October - examining a range of options, including retaining the business, spinning it...

Novartis said in an emailed statement it had made good progress in implementing its new organisational structure that involved integrating ...

Even once such a vaccine is on the market, Novartis AG Chief Executive Officer Vas Narasimhan said, it probably won’t protect everyone -- a...

The settlement of the lawsuit was announced by Acting Manhattan U.S. Attorney Audrey Strauss, who said the company splurged on "speaking fe...

Even as there is still question hanging over the efficacy of hydroxychloroquine (HCQ) as medication for Covid-19, Swiss drug maker Novartis...

Novartis has reached an agreement with U.S. regulators to hold a randomized trial of generic malaria drug hydroxychloroquine against COVID-...

Novartis AG on Thursday scrapped the $1 billion sale of U.S. generic pill and skin drug assets to India's Aurobindo Pharma Ltd as regulator...

Other companies including Bayer and Teva have also agreed to donate hydroxychloroquine or similar drugs, while Gilead Sciences is testing i...

In the absence of sustained investments by government, the cure for epidemics such as Covid-19 becomes a challenge, Novartis global CEO Vas...

Novartis will cut about 2,200 jobs in Switzerland over the next four years as it consolidates production and shifts positions elsewhere to ...

GSK is initiating a strategic review of Horlicks and its other consumer healthcare nutrition products to support funding the Novartis deal.

Vas Narasimhan from Novartis; Rajeev Suri from Nokia & Punit Renjen from Deloitte were part of the dinner that took place on the sidelines ...

Here’s everything that you need to know about the doctor-turned-CEO.

As many as five Indians have featured in this year's Fortune 40 under 40 list, an annual ranking of the most influential young people in th...